CA
NZ
UK
AU
IND
US
…
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -24.70M | -19.58M | -11.98M | -11.32M | -15.51M |
| Net income | -24.87M | -19.58M | -11.98M | -11.32M | -15.51M |
| Selling general administrative | 7.44M | 5.16M | 4.57M | 4.69M | 2.62M |
| Gross profit | -0.01M | -0.02M | -0.01M | -3.73M | -0.17M |
| Reconciled depreciation | 0.00M | 0.01M | 0.01M | 0.25M | 0.13M |
| Ebit | -26.46M | -19.58M | -11.84M | -8.43M | -4.89M |
| Ebitda | -26.45M | -19.56M | -11.84M | -8.09M | -4.72M |
| Depreciation and amortization | 0.01M | 0.01M | 0.01M | 0.34M | 0.17M |
| Operating income | -26.46M | -19.38M | -11.66M | -8.43M | -6.65M |
| Other operating expenses | 26.46M | 19.38M | 11.66M | 8.43M | 6.65M |
| Interest expense | - | 0.00M | 0.13M | 0.00M | 0.77M |
| Tax provision | 0.17M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 1.36M | 0.96M | 1.00M | 0.05M | 0.01M |
| Net interest income | 1.36M | 0.96M | 0.87M | 0.05M | -0.77M |
| Income tax expense | 0.17M | - | - | 0.01M | -0.04M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 26.46M | 19.38M | 11.66M | 4.69M | 4.63M |
| Cost of revenue | 0.01M | 0.02M | 0.01M | 3.73M | 0.17M |
| Total other income expense net | 1.76M | -0.20M | -0.32M | -2.89M | -8.86M |
| Net income from continuing ops | -24.87M | -19.58M | -11.98M | -8.34M | -12.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 31.89M | 50.88M | 44.30M | 6.14M | 9.87M |
| Intangible assets | - | - | 3.92M | 3.88M | 5.60M |
| Other current assets | 3.80M | 1.76M | 0.73M | 0.05M | 0.03M |
| Total liab | 4.11M | 3.59M | 3.62M | 2.80M | 1.65M |
| Total stockholder equity | 27.78M | 47.28M | 40.67M | 3.34M | 8.22M |
| Other current liab | 2.26M | 1.52M | 2.58M | 1.35M | 0.76M |
| Common stock | 85.83M | 73.67M | 61.92M | 29.91M | 22.21M |
| Capital stock | 85.83M | 73.67M | 46.67M | 22.26M | 22.21M |
| Retained earnings | -81.97M | -52.68M | -47.50M | -31.30M | -15.91M |
| Other assets | - | - | - | -0.00M | 0.00M |
| Cash | 9.80M | 40.18M | 22.07M | 1.90M | 3.82M |
| Total current liabilities | 4.11M | 3.59M | 3.62M | 2.80M | 1.65M |
| Net debt | -9.80M | -40.18M | -22.07M | -1.90M | -3.82M |
| Other stockholder equity | 25.65M | 26.44M | 8.50M | 4.73M | 1.93M |
| Total current assets | 31.88M | 50.87M | 40.32M | 2.21M | 4.27M |
| Long term investments | 0.00M | 0.00M | 0.03M | 0.03M | 0.00M |
| Short term investments | 17.91M | 8.50M | 17.52M | - | - |
| Net receivables | 0.37M | 0.44M | 0.44M | 0.26M | 0.41M |
| Accounts payable | 1.77M | 2.07M | 1.04M | 1.45M | 0.89M |
| Accumulated other comprehensive income | -1.72M | -0.15M | 17.76M | -0.01M | -0.00M |
| Non currrent assets other | - | - | -0.97M | - | - |
| Non current assets total | 0.01M | 0.00M | 3.98M | 3.93M | 5.60M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -9.41M | 4.42M | -13.21M | 0.00M | - |
| Total cashflows from investing activities | -9.42M | 4.42M | -17.54M | -0.00M | 1.36M |
| Net borrowings | - | 0.00M | -0.28M | 0.00M | 0.15M |
| Total cash from financing activities | 2.24M | 37.27M | 50.95M | 2.75M | 5.84M |
| Net income | -24.87M | -19.58M | -15.89M | -8.34M | -12.16M |
| Change in cash | -30.27M | 24.80M | 21.27M | -1.17M | 3.26M |
| Begin period cash flow | 40.07M | 15.38M | 1.92M | 4.87M | 0.56M |
| End period cash flow | 9.80M | 40.18M | 22.07M | 1.92M | 3.82M |
| Total cash from operating activities | -23.60M | -17.40M | -14.42M | -5.66M | -3.95M |
| Issuance of capital stock | 0.00M | 29.82M | 24.47M | 2.04M | 5.55M |
| Depreciation | 0.00M | 0.01M | 0.01M | 0.25M | 0.13M |
| Other cashflows from investing activities | - | - | -4.32M | -0.00M | - |
| Dividends paid | - | - | 0.00M | 0.00M | - |
| Change to account receivables | 0.07M | -0.03M | -0.24M | 0.20M | -0.05M |
| Other cashflows from financing activities | - | 7.44M | 26.77M | 0.70M | 0.15M |
| Capital expenditures | 0.01M | 0.00M | 0.02M | 0.00M | 0.01M |
| Change in working capital | -1.48M | -0.71M | 0.28M | 0.73M | -0.38M |
| Stock based compensation | 3.23M | 1.47M | 1.64M | 1.06M | 0.76M |
| Other non cash items | -0.48M | 1.40M | -0.45M | 0.64M | 7.70M |
| Free cash flow | -23.60M | -17.41M | -14.44M | -4.26M | -3.95M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. Common Stock |
0.84 13.23% |
7.19 | - | - | - | 3.47 | 4.75 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director | 1955 |
| Ms. Elizabeth Williams C.A., CPA | CFO & Corporate Secretary | 1978 |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer | 1969 |
| Dr. Wildon Farwell M.D., M.P.H. | Chief Medical Officer | 1976 |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer | 1962 |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration | NA |
| Dr. Ryan Mitchell Ph.D. | Senior VP & Head of Corporate Development | NA |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A. | Strategic Advisor | 1960 |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy | 1952 |
| Ms. Desiree Chan | Chief of Staff | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...